Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

43.9K
Overview
43.9K
Antibiotic Selection00:57

Antibiotic Selection

52.2K
Overview
52.2K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

2.4K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.6K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete Genome Sequences of Fribs8, Alyssamiracle, MakoManhole and DaviePasture, Four <i>Gordonia rubripertincta</i> Bacteriophages from Different Clusters Isolated from Soil in Davie, Florida.

microPublication biology·2026
Same author

Menopause experience among people with criminal legal system involvement.

Menopause (New York, N.Y.)·2026
Same author

Laterally Implanted Pregnancy With Placenta Accreta Spectrum in a Nulliparous Patient: A Diagnostic Challenge.

Case reports in obstetrics and gynecology·2026
Same author

Teaching Effective Vaccine Recommendations.

Family medicine·2026
Same author

Operational and data-integrity limitations of a system-wide Epic OPAT order set: a three-year cohort analysis.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Refractory <i>Candidozyma</i> (<i>Candida</i>) <i>auris</i>-associated central nervous system infection in a postoperative neurosurgical patient.

ASM case reports·2026

Related Experiment Video

Updated: May 29, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.1K

Significant Publications on Infectious Diseases Pharmacotherapy in 2023.

Alex V Stabler1, Ricky Huynh-Phan2, Khyati Amin3

  • 1Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Journal of Pharmacy Practice
|February 6, 2025
PubMed
Summary
This summary is machine-generated.

This review summarizes key 2023 infectious diseases (ID) pharmacotherapy articles, highlighting advances in antimicrobial stewardship and treatment for various infections. It helps clinicians stay updated on practice-changing research in infectious disease pharmacotherapy.

Keywords:
anti-infectiveantimicrobial stewardshiphuman immunodeficiency virusinfectious diseasespharmacotherapy

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

12.8K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.6K

Related Experiment Videos

Last Updated: May 29, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.1K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

12.8K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.6K

Area of Science:

  • Infectious Diseases
  • Pharmacotherapy
  • Antimicrobial Stewardship

Background:

  • The field of infectious diseases (ID) pharmacotherapy is rapidly evolving.
  • Staying current with significant publications is crucial for clinical practice.
  • Advances in treating infections and managing antimicrobial resistance are ongoing.

Purpose of the Study:

  • To summarize the most significant infectious diseases (ID) pharmacotherapy articles published in 2023.
  • To highlight practice-changing research in general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy.
  • To aid clinicians in remaining current with recent ID pharmacotherapy literature.

Main Methods:

  • Nomination of notable articles by the Houston Infectious Diseases Network (HIDN).
  • Survey distributed to Society of Infectious Diseases Pharmacists (SIDP) members to identify top articles.
  • Selection and summarization of the most impactful publications from 2023.

Main Results:

  • 22 articles nominated for general ID pharmacotherapy, 9 for HIV/AIDS pharmacotherapy.
  • Survey identified top-voted articles based on SIDP member input.
  • Summaries focus on antimicrobial stewardship, treatment durations, new antimicrobials, and drug-resistant organisms.

Conclusions:

  • Continuous advancements in antimicrobial stewardship and infectious disease management.
  • The review aids clinicians in identifying key ID pharmacotherapy publications from 2023.
  • Emphasis on crucial areas like new antimicrobials and combating drug-resistant organisms.